05/18/22 8:00 AMNasdaq : AEZS conferencesAeterna Zentaris to Present at the H.C. Wainwright Global Investment ConferenceAeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products, today announced that Dr. KlausRHEA-AIneutral
05/16/22 8:00 AMNasdaq : AEZS Aeterna Zentaris Announces Virtual 2022 Meeting of Shareholders and Urges Shareholders to Vote in Favor of the Proposed Share ConsolidationAeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“ Aeterna ” or the “ Company ”), a specialty biopharmaceutical company commercializing and developing therapeutics and diagnostic tests, today announced that its Virtual Annual General and SpecialRHEA-AIneutral
05/12/22 8:05 AMNasdaq : AEZS clinical trialUpdate on Positive Pre-Clinical Results from AIM Biologicals Development Program for the Potential Treatment of Parkinson’s Disease– Data presented at IMMUNOLOGY2022 ™ , the A nnual Event of the American Association of Immunologists – Company advancing development of its Autoimmunity Modifying ( “ AIM ” ) Biologic al s as a potential therapeutic treatment option for Parkinson’s Disease (" PD ") TORONTO, ONTARIO, May 12, 2022RHEA-AIpositive
05/11/22 8:05 AMNasdaq : AEZS earningsAeterna Zentaris Reports First Quarter 2022 Financial Results and Provides Business OutlookAeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”),RHEA-AIneutral
04/25/22 8:05 AMNasdaq : AEZS Aeterna Zentaris Abstract Accepted for Presentation at IMMUNOLOGY2022™, the Annual Event of the American Association of ImmunologistsAeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS)RHEA-AIneutral
04/19/22 8:05 AMNasdaq : AEZS Aeterna Zentaris Secures New European Patent Related to Use of Macimorelin for the Diagnosis of Growth Hormone Deficiency in AdultsAeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” orRHEA-AIneutral
04/13/22 10:45 AMNasdaq : AEZS, CNSP, AREC JTC Team Announces Continuation of its Virtual Investor Spotlight Series with NASDAQ: AEZS, NASDAQ: CNSP, and NASDAQ: ARECJTC Team ("JTC"), a fully integrated corporate communications and investor relations firm, today announced the continuation of its Virtual Investor SpotlightRHEA-AIneutral
04/12/22 8:05 AMNasdaq : AEZS conferencesAeterna Zentaris to Participate at the Virtual Investor 2022 CEO SpotlightAeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), aRHEA-AIneutral
04/11/22 8:05 AMNasdaq : AEZS Aeterna Zentaris Abstract Accepted for Presentation at 13th International Congress on AutoimmunityAeterna Zentaris Inc. (NASDAQ: AEZS) (TSX:RHEA-AIneutral
03/29/22 8:00 AMNasdaq : AEZS earningsAeterna Zentaris Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business OutlookAeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS)RHEA-AIneutral